253 related articles for article (PubMed ID: 34278466)
1. Chemokine CCL20 promotes the paclitaxel resistance of CD44
Chen M; Su J; Feng C; Liu Y; Zhao L; Tian Y
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278466
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.
Chen J; Wang J; Chen D; Yang J; Yang C; Zhang Y; Zhang H; Dou J
BMC Cell Biol; 2013 Jan; 14():7. PubMed ID: 23368632
[TBL] [Abstract][Full Text] [Related]
3. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
4. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.
Liu W; Wang W; Wang X; Xu C; Zhang N; Di W
Cancer Lett; 2020 Mar; 472():59-69. PubMed ID: 31866467
[TBL] [Abstract][Full Text] [Related]
6. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway.
Guo W; Li H; Liu H; Ma X; Yang S; Wang Z
Oncol Rep; 2019 Sep; 42(3):1075-1089. PubMed ID: 31322256
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
8. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
9. lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.
Wei W; Zhao X; Zhu J; Zhang L; Chen Y; Zhang B; Li Y; Wang M; Zhang Z; Wang C
Oncol Rep; 2019 Nov; 42(5):1946-1956. PubMed ID: 31545478
[TBL] [Abstract][Full Text] [Related]
10. Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20-CCR6 axis.
Kano H; Izumi K; Hiratsuka K; Toriumi R; Nakagawa R; Aoyama S; Kamijima T; Shimada T; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Saito Y; Nakagawa-Goto K; Yoshioka K; Nakata H; Lin WJ; Mizokami A
Cancer Sci; 2023 Apr; 114(4):1479-1490. PubMed ID: 36479732
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
12. Loss of Krüppel-like factor 9 facilitates stemness in ovarian cancer ascites-derived multicellular spheroids via Notch1/slug signaling.
Wang K; Liu S; Dou Z; Zhang S; Yang X
Cancer Sci; 2021 Oct; 112(10):4220-4233. PubMed ID: 34363722
[TBL] [Abstract][Full Text] [Related]
13. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
15. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
17. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview.
Frick VO; Rubie C; Keilholz U; Ghadjar P
World J Gastroenterol; 2016 Jan; 22(2):833-41. PubMed ID: 26811629
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
19. Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.
Wang F; Zhang L; Liu J; Zhang J; Xu G
Aging (Albany NY); 2020 Jun; 12(11):11042-11060. PubMed ID: 32516753
[TBL] [Abstract][Full Text] [Related]
20. CCL20/CCR6 chemokine/receptor expression in bone tissue from osteoarthritis and rheumatoid arthritis patients: different response of osteoblasts in the two groups.
Lisignoli G; Manferdini C; Codeluppi K; Piacentini A; Grassi F; Cattini L; Filardo G; Facchini A
J Cell Physiol; 2009 Oct; 221(1):154-60. PubMed ID: 19492413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
